Nedaplatin
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Boniva · Iband
Bisphosphonate · approved 2003 · 9 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
The kidney-gentlest nitrogen bisphosphonate — renal events near placebo at standard doses.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Lower renal risk than zoledronate or pamidronate. In a 2-year phase III breast-cancer trial, adverse renal events with IV ibandronate were ~4% versus ~4.5% with placebo — essentially at background. Bisphosphonates as a class can cause toxic ATN (zoledronate) or collapsing FSGS (pamidronate), but ibandronate is the renal-safety outlier within the class. Reported rate: serum creatinine increase >=44.2 micromol/l in 2% — Women with breast cancer and bone metastases receiving intravenous ibandronate 6 mg every 3-4 weeks for up to 6 months,… (von 2008, PMID 18334511).Source: von Moos et al., Ann Oncol 2008 (serum creatinine rise >=44.2 micromol/l in 2/101; Jackson, Oncologist 2005 for the 4% vs 4.5% placebo comparison)
Acute when it occurs (days), related to dose and infusion rate; antiresorptive electrolyte effects within the first days.
Distilled from: “Acute when it occurs (days), related to dose and infusion rate; antiresorptive electrolyte effects within the first days.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Hypocalcemia ~16% in pooled long-term IV bisphosphonate cohort (incl. ibandronate); grade 3 renal toxicity 0.7%
Damage to the filtration barrier — podocyte injury, FSGS and protein leak from VEGF and mTOR blockade.
Tap a signature to trace where it strikes the nephron.
Representative incidence
Acute Tubular Necrosis strikes: Proximal Tubule, Distal Tubule / Collecting Duct.
Acute Tubular Necrosis
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Nitrogen-containing bisphosphonate that inhibits farnesyl pyrophosphate synthase in the mevalonate pathway of osteoclasts, disrupting prenylation of small GTPases (Ras/Rho/Rac), impairing osteoclast cytoskeleton and survival and thereby suppressing bone resorption. Used for malignancy-associated bone disease, hypercalcemia of malignancy and post-menopausal osteoporosis.
Class-level context for the major non-renal toxicities of the Bisphosphonate class.
Musculoskeletal
Myalgia, myositis, rhabdomyolysis, ONJ
7 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Aug 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
Ibandronate sodium is not recommended for use in patients with severe renal impairment (creatinine clearance less than 30 mL/min).
Kidney rows of the label's dosage tables
None of the newest openFDA labels for this product carries a dosage table. The label's prose can still give kidney instructions.
Everything below is FAERS — adverse events someone chose to report, about 14,757 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
586 of 14,757 reports
Reported with hospitalization
2,761 of 14,757 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 1,107 of the 14,757 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ibandronate sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Gleevec · BCR-ABL TKI
Fluid retention; rare Fanconi and AKI.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Datroway · Antibody-drug conjugate (TROP2/DXd)
2025 TROP2 ADC; renal signal theoretical, extrapolated from the ADC class.
Emrelis · c-Met ADC (MMAE)
c-Met MMAE antibody-drug conjugate; proximal tubular ATN risk extrapolated from the ADC/MMAE class.
Paraplatin · Platinum agent
Kidney-sparing; GFR-dosed by the Calvert formula.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Ibandronate’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Ibandronate; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 46 clinical records among all 73 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.